Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer: Updated survival and time to progression data. Yuen, A., Halsey, J., Fisher, G., Advani, R., Moore, M., Saleh, M., Ritch, P., Harker, G., Ahmed, F., Jones, C., Polikoff, J., Keiser, W., Kwoh, T. J., Holmlund, J., Dorr, A., Sikic, B. AMER ASSOC CANCER RESEARCH. 2001: 3681S
View details for Web of Science ID 000172121800140